Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma

Overview of attention for article published in Frontiers in oncology, October 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 2 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,713 followers.

RT @FrontOncology: New research: Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive adva…

02 Nov 2023

Reply Repost Favourite

New research: Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma: Objective Our study aimed to evaluate the cost-effectiveness of the addition of… https://t.co/

02 Nov 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.